Monitor actual repurchase execution and any updates on the broader $150 million authorization. The buyback provides a floor but does not address fundamental pipeline or revenue concerns. Watch for next quarterly results or pipeline catalysts for directional cues.
Price Chart
Executive Summary
Lakefront Biotherapeutics (formerly Galapagos) announced a $50 million share repurchase program, authorized through December 31, 2026, and executed via Morgan Stanley. The buyback is part of a broader $150 million repurchase opportunity stemming from the March 2026 Gilead transaction. The buyback alone does not offset the underlying operational and pipeline risks.
Key Facts
- Lakefront announced a $50 million share repurchase program, effective until December 31, 2026.
- The program is executed through Morgan Stanley & Co International PLC.
- The buyback is part of a $150 million repurchase opportunity from the March 2026 Gilead transaction.
- Purchased shares will be held as treasury shares.
- The company may suspend or stop the program at any time.
Financial Impact
$50 million share repurchase authorization, representing a portion of a $150 million total opportunity from the Gilead deal.
Risk Factors
- Buyback may be suspended or stopped at any time.
- Heavy bearish analyst consensus (83% bearish) suggests limited confidence in fundamentals.
- No revenue or earnings data provided in this filing to assess financial health.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004009 |
| Document: f6k_060926.htm | 0001171843-26-004009 |
| Document: 0001171843-26-004009-index-headers.html | 0001171843-26-004009 |
| Document: 0001171843-26-004009-index.html | 0001171843-26-004009 |
| Document: 0001171843-26-004009.txt | 0001171843-26-004009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 19w ago | 6-K | $28.08 $28.08 | · 0.00% | ▼ −3.89% | $31.95 (+13.78%) |
Jun 9, 2026 20w ago | 6-K | $28.08 $28.08 | · 0.00% | ▼ −1.39% | $31.95 (+13.78%) |
Apr 29, 2026 25w ago | 6-K | $28.08 $28.08 | · 0.00% | ▼ −6.05% | $31.95 (+13.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers